The midlife man no one talks about — the andropause analog
9 min read · Uplevel editorial
You know what menopause is. Everyone does — not well enough, the cultural literacy there is still far below what it should be, but the word exists, the concept has a name, and when a woman describes the experience her doctor will at minimum recognize it as a hormonal transition worth investigating. The male equivalent — the gradual multi-system hormonal shift that happens in a man's late 40s and 50s — does not have that. You don't get a word that means anything to most people. You get "midlife crisis," which is a cultural joke. You get "aging," which closes the conversation. You get told it's normal, which is technically true and practically useless, because normal in the sense of common is not the same as normal in the sense of healthy or inevitable or nothing-to-be-done.
The experience, before the labels: you're 51, or 48, or 55. Your body composition has been shifting despite doing more or less the same things you've always done. Strength isn't where it was. The weight that used to come off when you tightened up the diet now requires significantly more effort for significantly less result. You're tired in a way that isn't quite fatigue — it's more like a reduction in reserve, a shorter battery, a quicker depletion. Sleep feels less restorative than it used to even when you're getting the hours. You're more irritable — short-fused in a way you don't entirely recognize, emotional regulation slightly less available. Libido is quieter. Motivation to pursue things, socially and professionally and physically, has a different quality — not absent, but muted. You might be depressed. Or you might be in a hormonal transition that has a similar surface presentation and a different set of causes.
Testosterone is part of the story but it is not all of it. The male hormonal landscape in midlife involves several overlapping systems declining simultaneously, and fixating on testosterone alone — which is where most clinical conversations land — misses most of the picture.
DHEA — dehydroepiandrosterone — declines with age in both men and women, a process called adrenopause or dehydroepiandrosterone sulfate decline that begins in the mid-20s and accelerates through midlife. DHEA is a precursor hormone, converting in peripheral tissues to both testosterone and estrogen, and it has receptor activity of its own in the brain and immune system. Its decline contributes to the broader androgenic shift of midlife, and it is a consistent finding in research on aging men that DHEA levels are substantially lower than youthful levels before testosterone has fallen to clinically recognized hypogonadal thresholds. It's largely ignored in standard evaluations.
Growth hormone declines with age in a pattern called somatopause. Peak GH secretion is in adolescence and early adulthood; by the late 40s, total GH output may be a fraction of what it was at 25. The driver of this decline is largely the loss of slow-wave sleep, which is when the pituitary releases its major GH pulse. Slow-wave sleep begins declining in the 30s and continues steadily through midlife. Less slow-wave sleep means smaller GH pulses means less tissue repair, less lipolysis, less lean mass maintenance, less recovery capacity. The resulting changes in body composition — more visceral fat, less muscle — are not just consequences of declining testosterone. They are consequences of declining GH, and treating testosterone while ignoring GH physiology addresses half the problem.
Cortisol patterns shift as well. Chronically elevated cortisol — from the accumulation of years of sustained occupational, relational, and financial stress — is directly antagonistic to the hormonal landscape of vitality. Cortisol competes with testosterone in biosynthetic pathways. Cortisol degrades the architecture of the prefrontal cortex and limbic system over time. Cortisol is directly antagonistic to slow-wave sleep. The midlife man who has been in a sustained high-cortisol state for a decade is experiencing hormonal suppression from above, driven by the chronic activation of stress circuitry, layered on top of the age-related decline of the hormonal systems underneath.
Sleep architecture is not incidental to this. The sleep changes of midlife — less slow-wave, more fragmented REM, worse overall continuity — are both a consequence of hormonal changes and a driver of them. Poor slow-wave sleep blunts the GH pulse. Fragmented REM disrupts emotional regulation and cortisol clearance. The circadian timing of testosterone release, which peaks in morning slow-wave, is disrupted by the same architecture changes. Sleep apnea — far more common in midlife men, particularly with increasing weight and pharyngeal tissue changes — adds a layer of chronic intermittent hypoxia that directly suppresses testosterone production at the Leydig cell level and fragments every stage of sleep architecture. It is remarkable how often a sleep apnea workup is not part of the evaluation of a midlife man presenting with fatigue, mood changes, and hormonal symptoms.
The microbiome shifts matter more than is generally appreciated. Gut microbial diversity declines with age. The microbiome plays a role in estrogen metabolism — the estrobolome, a subset of gut bacteria, produces enzymes that recirculate estrogens from the gut back into systemic circulation. Changes in the microbiome alter this recycling and can shift estrogen balance. The gut-brain axis connection means that microbiome changes affect neurotransmitter production, mood, and inflammatory signaling. These are not peripheral considerations. They are part of the multi-system picture of midlife hormonal transition.
The conventional medicine response to this picture is often fragmented in the wrong way. Testosterone might be addressed — with TRT if levels are below threshold, with nothing if they're technically in range. Mood might be addressed with an antidepressant that has its own sexual and hormonal side effects. Sleep is often addressed by prescribing a Z-drug or benzodiazepine, which produces sedation while actively suppressing slow-wave architecture. Nothing is done about GH or DHEA. Nothing about the microbiome. Nothing about the cortisol load that's driving half of the suppression. The interventions address symptoms in isolation without attending to the system.
Peptide approaches in this context represent an area where the mechanism and the research interest are both genuine and the evidence base is incomplete — which is true of most things in longevity medicine, because the research methodologies to study multi-system interventions over the timescales that matter are difficult and expensive. Sermorelin and ipamorelin are GH-axis peptides that work through the upstream GHRH receptor, prompting the pituitary to release GH through the preserved feedback system. They've been researched for their potential to support slow-wave sleep, GH pulse amplitude, recovery, and body composition in adults with age-related GH decline. The feedback-governed mechanism limits the risk of supraphysiological GH effects that exogenous HGH can produce. The appropriate context is a GH-axis evaluation with IGF-1 measurement and specialist oversight, not self-administration.
MOTS-c is a mitochondrial-derived peptide — encoded in the mitochondrial genome rather than the nuclear genome — that has been researched for its role in metabolic regulation, insulin sensitivity, and stress response. The research is early and largely preclinical or small-scale human studies, but the mechanism is distinct and represents a genuinely different angle on the metabolic component of male aging: supporting mitochondrial function in cells that have accumulated mitochondrial dysfunction with age and oxidative stress. NAD+ and its precursors work through similar mitochondrial energy pathways. The evidence for NAD+ precursor supplementation in aging is more developed than for MOTS-c, though still far from definitive.
The foundational interventions deserve the emphasis they're given in serious men's health medicine, because they are load-bearing in a way that no peptide or supplement replaces. Strength training has direct positive effects on testosterone, GH pulse amplitude, insulin sensitivity, sleep slow-wave pressure, and mood. Protein intake adequate to support muscle protein synthesis — consistently higher than the population average, particularly in men over 45 — is a metabolic foundation. Sleep quality is the most leverage-producing intervention in the picture: improving slow-wave architecture by addressing apnea, reducing evening alcohol, establishing consistent timing, and managing cortisol in the evening creates downstream benefits in testosterone, GH, recovery, body composition, and emotional regulation that no single compound can replicate. Social engagement and purposeful activity have measurable effects on testosterone and inflammatory markers. These are not soft recommendations. They are mechanistically grounded interventions with effects measurable in blood.
What the midlife man deserves is a comprehensive evaluation that takes the multi-system nature of this transition seriously: testosterone panel with free T and SHBG, LH and FSH, estradiol, prolactin, DHEA-S, IGF-1 as a GH-axis surrogate, thyroid function, fasting metabolic panel, sleep apnea screening, and a clinical conversation about what he's actually experiencing. Not a single-number reassurance that everything is in range. Not an immediate jump to TRT without evaluating the full picture. A real reckoning with the system as a system, and a treatment philosophy that addresses the upstream drivers alongside whatever pharmacological or peptide support may be appropriate for his specific picture.
The name for what he's experiencing doesn't matter as much as the clinical recognition that something real is happening, that it has identifiable mechanisms, and that those mechanisms have addressable components. That recognition is what the conventional medical encounter often fails to provide. Finding a provider who can offer it — a urologist, endocrinologist, or men's health specialist with a multi-system orientation — is not a luxury. It is the starting point for addressing the midlife transition in a way that actually fits the problem.
Frequently asked